Physician profile
Jonathan S Koelle
NPI 1609803824
$1,678.90
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $403 · 2020: $53.41 · 2021: $427 · 2022: $251 · 2023: $544.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $544.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $543.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $396.57 | 2022-2023 | Uzedy, Austedo, Austedo Xr |
| Neurocrine Biosciences, INC. | $374.97 | 2019-2021 | |
| Abbvie INC. | $234.48 | 2021-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $109.79 | 2021 | |
| Merck Sharp & Dohme LLC | $89.61 | 2019-2022 | |
| Corium, LLC | $63.66 | 2023 | Azstarys |
| Lundbeck LLC | $60.17 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $49.72 | 2022 | |
| Neuronetics, INC. | $48.80 | 2022 | |
| Sunovion Pharmaceuticals INC. | $42.16 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.12 | 2019 | |
| Idorsia Pharmaceuticals US INC | $37.75 | 2022-2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $35.21 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $33.97 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $26.41 | 2023 | Qelbree |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $26.26 | 2019 | |
| Allergan, INC. | $11.25 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Koelle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.